Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Pathway”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Early research (Phase 1)Not Yet RecruitingNCT07318324
What this trial is testing

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Who this might be right for
Phase IBAvutometinibRAS Pathway+1 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT05340621
What this trial is testing

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Who this might be right for
RAS MutationNRAS Gene MutationMelanoma
OnKure, Inc. 36
Testing effectiveness (Phase 2)Ended earlyNCT03504501
What this trial is testing

Synaptic Plasticity and Cognitive Function in RASopathies

Who this might be right for
Impaired Synaptic PlasticityImpaired Cognition
Technical University of Munich 16
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Early research (Phase 1)Study completedNCT01960374
What this trial is testing

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

Who this might be right for
Healthy Volunteers Pharmacokinetic Study
AstraZeneca 117
Early research (Phase 1)Temporarily pausedNCT05111561
What this trial is testing

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+2 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Study completedNCT03429803
What this trial is testing

DAY101 In Gliomas and Other Tumors

Who this might be right for
Low-grade Glioma
Karen D. Wright, MD 44
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)WithdrawnNCT06284460
What this trial is testing

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Who this might be right for
Pathway Mutant Myelodysplastic SyndromesMyelodysplastic NeoplasmMyeloproliferative Neoplasm
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Early research (Phase 1)Active Not RecruitingNCT03162627
What this trial is testing

Selumetinib and Olaparib in Solid Tumors

Who this might be right for
Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital Organs+2 more
M.D. Anderson Cancer Center 90
Testing effectiveness (Phase 2)Ended earlyNCT03002623
What this trial is testing

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Who this might be right for
Thyroid NeoplasmsPoorly Differentiated and Undifferentiated Thyroid CancerDifferentiated Thyroid Cancer
National Cancer Institute (NCI) 7
Testing effectiveness (Phase 2)Study completedNCT00098254
What this trial is testing

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT07549646
What this trial is testing

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Who this might be right for
Ras/MAPK Pathway Vascular AnomaliesVascular AnomaliesVascular Anomaly
Children's Hospital of Philadelphia 45
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Testing effectiveness (Phase 2)Looking for participantsNCT05554328
What this trial is testing

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 165
Testing effectiveness (Phase 2)Ended earlyNCT03705507
What this trial is testing

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, Pediatric+2 more
University of Birmingham 12
Testing effectiveness (Phase 2)Study completedNCT02285439
What this trial is testing

Study of MEK162 for Children With Low-Grade Gliomas

Who this might be right for
Low-Grade GliomasMalignant Neoplasms, BrainSoft Tissue Neoplasms
Children's Hospital Los Angeles 105
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Not applicableUnknownNCT06331117
What this trial is testing

Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies

Who this might be right for
RASopathyCostello SyndromeNoonan Syndrome+1 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120
Load More Results